Blueprint Medicines (NASDAQ:BPMC) has been assigned a $82.00 price target by analysts at Raymond James Financial in a research report issued on Sunday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Raymond James Financial’s target price indicates a potential upside of 14.11% from the stock’s previous close.

A number of other equities research analysts have also weighed in on the company. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research note on Friday, November 10th. Morgan Stanley upped their target price on Blueprint Medicines from $45.00 to $78.00 and gave the company an “overweight” rating in a research report on Monday, October 23rd. Jefferies Group reiterated a “buy” rating and issued a $56.00 target price on shares of Blueprint Medicines in a research report on Tuesday, September 5th. Canaccord Genuity reiterated a “buy” rating and issued a $80.00 target price (up previously from $66.00) on shares of Blueprint Medicines in a research report on Wednesday, November 1st. Finally, Zacks Investment Research upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company’s stock. Blueprint Medicines presently has an average rating of “Buy” and an average target price of $81.56.

Shares of Blueprint Medicines (BPMC) traded up $0.30 during mid-day trading on Friday, hitting $71.86. The stock had a trading volume of 296,800 shares, compared to its average volume of 427,879. Blueprint Medicines has a 1-year low of $25.34 and a 1-year high of $77.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.06). Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The business had revenue of $8.07 million for the quarter, compared to analysts’ expectations of $5.35 million. During the same quarter in the previous year, the firm posted ($0.62) EPS. Blueprint Medicines’s revenue was up 31.0% on a year-over-year basis. sell-side analysts predict that Blueprint Medicines will post -3.76 EPS for the current year.

In other Blueprint Medicines news, insider Anthony L. Boral sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $70.40, for a total value of $352,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Daniel Lynch sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $60.00, for a total value of $150,000.00. Following the completion of the sale, the director now owns 209,342 shares in the company, valued at approximately $12,560,520. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,639 shares of company stock worth $4,871,743. 3.40% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. California Public Employees Retirement System raised its stake in shares of Blueprint Medicines by 48.3% during the 3rd quarter. California Public Employees Retirement System now owns 9,197 shares of the biotechnology company’s stock worth $641,000 after buying an additional 2,997 shares during the period. Jane Street Group LLC acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth approximately $1,199,000. Cornerstone Capital Management Holdings LLC. acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth approximately $1,184,000. Alyeska Investment Group L.P. acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth approximately $6,967,000. Finally, First Republic Investment Management Inc. acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth approximately $293,000. Institutional investors and hedge funds own 91.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Raymond James Financial Reiterates $82.00 Price Target for Blueprint Medicines (BPMC)” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/11/raymond-james-financial-reiterates-82-00-price-target-for-blueprint-medicines-bpmc.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.